Nothing new they would be interested in the topic. But the scale on these interactions is advancing.
Big pharma turns to artificial intelligence to speed drug discovery, GSK signs deal By Ben Hirschler
LONDON (Reuters) - The world's leading drug companies are turning to artificial intelligence to improve the hit-and-miss business of finding new medicines, with GlaxoSmithKline unveiling a new $43 million deal in the field on Sunday.
Other pharmaceutical giants including Merck & Co, Johnson & Johnson and Sanofi are also exploring the potential of artificial intelligence (AI) to help streamline the drug discovery process.
The aim is to harness modern supercomputers and machine learning systems to predict how molecules will behave and how likely they are to make a useful drug, thereby saving time and money on unnecessary tests.
AI systems already play a central role in other high-tech areas such as the development of driverless cars and facial recognition software.
"Many large pharma companies are starting to realise the potential of this approach and how it can help improve efficiencies," said Andrew Hopkins, chief executive of privately owned Exscientia, which announced the new tie-up with GSK. .... "
Showing posts with label medicaid. Show all posts
Showing posts with label medicaid. Show all posts
Monday, July 03, 2017
Wednesday, June 17, 2015
Merck and Innovation
3 ways Merck is shaking up its innovation programs
'... Like most pharmaceutical companies, Merck has struggled in recent years with regulatory pressures and new technologies. To stay competitive, the firm is seeking to implement a "lean-startup software ethic" while establishing repeatable processes that can keep new ideas flowing. "Change and innovation are choices, not givens, in any organization, and there are managerial levers for making these selections wisely," write Frank Cespedes, Jay Galeota and Michael Wong ... "
'... Like most pharmaceutical companies, Merck has struggled in recent years with regulatory pressures and new technologies. To stay competitive, the firm is seeking to implement a "lean-startup software ethic" while establishing repeatable processes that can keep new ideas flowing. "Change and innovation are choices, not givens, in any organization, and there are managerial levers for making these selections wisely," write Frank Cespedes, Jay Galeota and Michael Wong ... "
Sunday, March 10, 2013
Recognizing Pattern with Math
Recognizing Patterns
With today’s powerful data analysis systems, users gather a ton of information—a breakdown of Wal-Mart Stores’ (WMT) sales in the U.S. or things people “like” on Facebook (FB)—in one place and then run queries. The questioner typically comes in with a preconceived idea of what he’s looking for or at least a set of preconceived biases that determine the questions he asks.
The Ayasdi software, which customers including Merck and Raytheon have been testing for several months, runs dozens of algorithms and then illuminates patterns and relations between the data points. BN ImmunoTherapeutics, for example, has turned to the software for research help on Prostvac, a prostate cancer vaccine that is undergoing clinical trials. The researchers compare genetic markers, people’s ages, medical histories, and other factors to figure out which patients will most likely benefit from the vaccine. “In the past, we would form a hypothesis and say, ‘We think these three biomarkers are important,’ ” says Amanda Enstrom, a research scientist at BN ImmunoTherapeutics. “With Ayasdi, we really allow the data to show us what the important biomarkers are.”
of information—a breakdown of Wal-Mart Stores’ (WMT) sales in the U.S. or things people “like” on Facebook (FB)—in one place and tWith today’s powerful data analysis systems, users gather a ton hen run queries. The questioner typically comes in with a preconceived idea of what he’s looking for or at least a set of preconceived biases that determine the questions he asks.
With today’s powerful data analysis systems, users gather a ton of information—a breakdown of Wal-Mart Stores’ (WMT) sales in the U.S. or things people “like” on Facebook (FB)—in one place and then run queries. The questioner typically comes in with a preconceived idea of what he’s looking for or at least a set of preconceived biases that determine the questions he asks.
The Ayasdi software, which customers including Merck and Raytheon have been testing for several months, runs dozens of algorithms and then illuminates patterns and relations between the data points. BN ImmunoTherapeutics, for example, has turned to the software for research help on Prostvac, a prostate cancer vaccine that is undergoing clinical trials. The researchers compare genetic markers, people’s ages, medical histories, and other factors to figure out which patients will most likely benefit from the vaccine. “In the past, we would form a hypothesis and say, ‘We think these three biomarkers are important,’ ” says Amanda Enstrom, a research scientist at BN ImmunoTherapeutics. “With Ayasdi, we really allow the data to show us what the important biomarkers are.”
of information—a breakdown of Wal-Mart Stores’ (WMT) sales in the U.S. or things people “like” on Facebook (FB)—in one place and tWith today’s powerful data analysis systems, users gather a ton hen run queries. The questioner typically comes in with a preconceived idea of what he’s looking for or at least a set of preconceived biases that determine the questions he asks.
Monday, February 04, 2013
Data Company Emerges from Stanford Math
In BusinessWeek:
With today’s powerful data analysis systems, users gather a ton of information—a breakdown of Wal-Mart Stores’ (WMT) sales in the U.S. or things people “like” on Facebook (FB)—in one place and then run queries. The questioner typically comes in with a preconceived idea of what he’s looking for or at least a set of preconceived biases that determine the questions he asks.
The Ayasdi software, which customers including Merck and Raytheon have been testing for several months, runs dozens of algorithms and then illuminates patterns and relations between the data points. BN ImmunoTherapeutics, for example, has turned to the software for research help on Prostvac, a prostate cancer vaccine that is undergoing clinical trials. The researchers compare genetic markers, people’s ages, medical histories, and other factors to figure out which patients will most likely benefit from the vaccine. “In the past, we would form a hypothesis and say, ‘We think these three biomarkers are important,’ ” says Amanda Enstrom, a research scientist at BN ImmunoTherapeutics. “With Ayasdi, we really allow the data to show us what the important biomarkers are.” ...
With today’s powerful data analysis systems, users gather a ton of information—a breakdown of Wal-Mart Stores’ (WMT) sales in the U.S. or things people “like” on Facebook (FB)—in one place and then run queries. The questioner typically comes in with a preconceived idea of what he’s looking for or at least a set of preconceived biases that determine the questions he asks.
The Ayasdi software, which customers including Merck and Raytheon have been testing for several months, runs dozens of algorithms and then illuminates patterns and relations between the data points. BN ImmunoTherapeutics, for example, has turned to the software for research help on Prostvac, a prostate cancer vaccine that is undergoing clinical trials. The researchers compare genetic markers, people’s ages, medical histories, and other factors to figure out which patients will most likely benefit from the vaccine. “In the past, we would form a hypothesis and say, ‘We think these three biomarkers are important,’ ” says Amanda Enstrom, a research scientist at BN ImmunoTherapeutics. “With Ayasdi, we really allow the data to show us what the important biomarkers are.” ...
Monday, May 28, 2012
Predictive Analytics and Medicaid Fraud
A good example of using predictive analytics with medical data. Here with billing data: " ... "The beauty of this system is that it recognizes patterns of billing behavior that don't fit in with the norm and then takes it a step further by looking for relationships among providers that can point us to a Web of suspicious accounts," Al Delia, North Carolina DHHS acting secretary, wrote in an IBM blog post. ... "
Subscribe to:
Posts (Atom)